CLE-043
Epilepsy and Major Depressive Disorder
PreclinicalActive
Key Facts
Indication
Epilepsy and Major Depressive Disorder
Phase
Preclinical
Status
Active
Company
About Clexio Biosciences
Israeli biotech developing NMDA‑antagonist and KV7‑channel therapies for depression and epilepsy.
View full company profile